| capecitabine / Generic mfg. |
2017-002037-31: Study of the impact of DPD activity on the efficacy of capecitabine Etude de l’impact de l’activité DPD sur l’efficacité de la capécitabine |
|
|
| Not yet recruiting | 4 | 155 | Europe | Tablet, Xeloda | Centre Antoine-LACASSAGNE, Centre Antoine-LACASSAGNE, DGOS | Metastatic HER2-negative breast cancer, Metastatic breast cancer with negative HER2-Receptors, Diseases [C] - Cancer [C04] | | | | |
2020-001938-35: AIRE: Investigation of the immune response after chemotherapy treatment with Eribulin: A trial for female patients with advanced breast cancer. AIRE: Untersuchung der Immunantwort nach Behandlung mit der Chemotherapie Eribulin: Eine Studie für Patientinnen mit fortgeschrittenem Brustkrebs. |
|
|
| Not yet recruiting | 4 | 84 | Europe | Eribulin, Paclitaxel, Paclitaxel Albumin-Bound, Capecitabine, Vinorelbine, Solution for injection, Concentrate for solution for infusion, Powder for solution for infusion, Tablet, Halaven, Paclitaxel, nab-Paclitaxel, Capecitabine, Vinorelbine | Institut für Frauengesundheit GmbH, Institut für Frauengesundheit (IFG) GmbH | Female patients diagnosed with HER2 negative advanced breast cancer, which had received at least one previous chemotherapy Patientinnen, die mit einem HER2 negativen Brustkrebs im fortgeschrittenem Stadium diagnostiziert wurden und zuvor mindestens eine Chemotherapie erhielten., Female patients which were diagnosed with advanced breast cancer. The tumor should not have a certain marker (HER2) on its surface (HER2 negative breast cancer). Patientinnen, die mit einem Brustkrebs im fortgeschrittenem Stadium diagnostiziert wurden. Den Tumorzellen fehlt ein bestimmter Marker (HER2) auf der Oberfläche (HER2-negativer Brustkrebs)., Diseases [C] - Cancer [C04] | | | | |
PADMA, NCT03355157 / 2016-004482-89: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - Study). |
|
|
| Recruiting | 4 | 150 | Europe | Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen) | German Breast Group, Pfizer, AMS Advanced Medical Services GmbH | Metastatic Breast Cancer | 03/23 | 03/23 | | |
NCT06387368: Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer |
|
|
| Not yet recruiting | 4 | 488 | NA | Huaier Granule, Z20000109#NMPA Approval Number#, Capecitabine, Standard chemotherapy | Health Science Center of Xi'an Jiaotong University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Pancreatic Cancer Non-resectable | 03/28 | 08/28 | | |
NCT06368063: The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer |
|
|
| Recruiting | 4 | 642 | RoW | Huaier granule, Z20000109#NMPA Approval Number#, chemotherapy drugs, Standard chemotherapy | Health Science Center of Xi'an Jiaotong University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Pancreatic Cancer Resectable | 03/26 | 03/28 | | |
ChiCTR2300068266: Tirelizumab plus Lunvatinib and capecitabine for first-line treatment of advanced intrahepatic cholangiocarcinoma unsuitable for GP chemotherapy |
|
|
| Not yet recruiting | 4 | 36 | China | 1. Tirelizumab: 200mg, q3w, intravenous drip, lasting for 1 year, or until the disease progresses or intolerable adverse reactions occur; 2. Remvastinib: 8mg, qd, oral, until the disease progresses or intolerable adverse reactions occur; 3. Capecitabine: 1000mg/m2, bid, oral, take it for 2 weeks, stop for 1 week | The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) ; The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), BeiGene (Beijing), Ltd. | advanced intrahepatic cholangiocarcinoma | | | | |
NCT05498766: Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients |
|
|
| Not yet recruiting | 4 | 702 | RoW | Huaier granule, Z20000109, Oxaliplatin, Tegafur, Gimeracil and Oteracil Potassium | Wuhan Union Hospital, China, LinkDoc Technology (Beijing) Co. Ltd. | Gastric Cancer | 07/29 | 11/29 | | |
